1. Introduction {#sec1}
===============

Postoperative cardiac events (CE) are associated with significant morbidity and mortality \[[@bib1], [@bib2], [@bib3], [@bib4]\]. It is estimated that of the 100, 000, 000 patients undergoing noncardiac surgery worldwide, approximately 500,000 to 900,000 experience perioperative CE \[[@bib2]\]. In-hospital mortality rates have ranged from 15% to 25% for myocardial infarction \[[@bib2],[@bib3]\], and as high as 65% for cardiac arrest \[[@bib4]\]. The high mortality and morbidity rates associated with postoperative CE make it a necessity to improve surgical outcomes through risk stratification and optimal perioperative management.

Previous studies have proposed cardiac risk indices in patients undergoing noncardiac surgery \[[@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15]\]; however, their application and generalizability is debatable. For example, the first substantiated cardiac risk index, published by Goldman and colleagues \[[@bib5]\] in 1977, has been criticized for having a low positive predictive value of 21.6% \[[@bib3]\]. Similarly, the revised cardiac index by Lee and colleagues \[[@bib6]\] over-represents patients who underwent thoracic and orthopedic surgery \[[@bib3]\] and has insufficient likelihood ratio for identifying patients with greater cardiac risks \[[@bib16]\], limiting its accurate prediction of CE in general or vascular surgery patients. In fact, even the accepted revised cardiac risk index by the American Heart Association and the American College of Cardiologists has been noted to underestimate the risk of CE in patients undergoing major noncardiac surgery \[[@bib7]\].

In view of limitations of previous CE risk indices, the present study seeks to understand and define in greater depth risk factors that accurately predict postoperative CE after major general and vascular surgery to allow for appropriate preoperative optimization, surgical management and informed consent. It is the hope of the authors that tailored perioperative management that targets identified risk factors will be employed to decrease CE-associated morbidity and mortality.

2. Methods {#sec2}
==========

Adult patients, aged 18 years and older, who underwent major surgery from 2013 to 2016 at an urban teaching hospital were retrospectively reviewed. Patients who had general or vascular surgery were included. The list of types of operations included in the study and their current procedural terminology (CPT) codes is shown in [Table 7](#tbl7){ref-type="table"}. Patients excluded were those with missing variables of interest. [Fig. 1](#fig1){ref-type="fig"} shows a flow chart for patients included and excluded in the study.Fig. 1Flow chart of inclusion and exclusion of patients.Fig. 1

The primary outcome in this analysis was 30-day postoperative CE, defined as myocardial infarction or cardiac arrest within the 30-day postoperative period.

Preoperative and operative variables analyzed included age, gender, body mass index, race, American Society of Anesthesiologists (ASA) status, emergency surgery, diabetes, smoking history, dyspnea, dependent functional status, ventilator dependence, congestive heart failure, chronic obstructive pulmonary disease, hypertension, acute renal failure or dialysis, disseminated cancer, wound infection, steroid use, weight loss, bleeding disorder, preoperative red blood cell (RBC) transfusion, systemic sepsis, serum sodium, blood urea nitrogen, creatinine, albumin, total bilirubin, aspartate aminotransferase (SGOT), alkaline phosphatase, white blood count, hematocrit, platelet count, partial thromboplastin time, international normalized ratio, and operative time.

Thirty-day outcomes analyzed included mortality, pulmonary complications (pneumonia, unplanned reintubation, prolonged mechanical ventilation), renal failure, neurological complications (stroke or cerebrovascular accidents), thrombotic complications (deep venous thrombosis, pulmonary embolism), wound infection, postoperative RBC transfusion, readmission, unplanned return to operating room, and prolonged hospitalization (length of hospital stay \>8 days).

3. Statistical analysis {#sec3}
=======================

Statistical analyses were performed using SPSS software (Version 22, Chicago, IL, USA). Patients were classified into those who experienced at least one postoperative CE and those who did not. Univariate analysis was performed on patient demographics, preoperative variables and postoperative outcomes. Baseline characteristics were compared using X^2^ tests for categorical variables and two-tailed *t*-test for continuous variables. Variables with P values less than 0.05 in the univariate analysis were included in a stepwise multivariate regression model. The stepwise multivariate regression models were utilized to identify predictors of UPR and the associations between CE and other postoperative outcomes. Additional subgroup analyses were conducted by classifying patients into surgical specialties-general or vascular surgery. All regression models were assessed using the Hosmer-Lemeshow test and *C* statistic for excellent goodness-of-fit and discrimination.

The study was approved by the Mount Sinai Beth Israel Hospital Institutional Review Board. This work has been reported in line with the STROCSS criteria \[[@bib17]\].

4. Results {#sec4}
==========

This study included 8441 patients who underwent vascular and general surgeries from 2013 to 2015 at our large urban teaching hospital, 157 (1.9%) of which experienced postoperative CE. In terms of demographics, patients who experienced postoperative CE were significantly older, white, less likely to be female, and were more likely to have comorbid conditions than those who did not ([Table 1](#tbl1){ref-type="table"}).Table 1Patient characteristics contributing to CE following general and vascular surgery, univariate and multivariate analyses.Table 1Patient characteristicsUnivariateMultivariateCE n = 157No CE n = 8284POR (95% CI)PAge \>65years72.6%35.3%\<0.014.9(3.4--6.9)\<0.01BMI\>30 kg/m^2^26.8%26.0%0.64Female gender49.0%51.0%0.61Race0.20 White70.1%65.2% Black21.7%18.2% Asian7.6%12.2% Other0.6%4.3%ASA\>368.8%15.5%\<0.0112.0(8.5--16.9)\<0.01Emergency surgery49.0%20.6%\<0.013.7(2.7--5.1)0.01Diabetes42.0%20.4%\<0.012.8(2.1--3.9)0.53Smoke15.9%16.5%0.840.96(0.62--1.5)0.39Dyspnea7.0%2.5%\<0.012.9(1.5--5.4)0.20Dependent functional status49.0%11.0%\<0.017.8(5.7--10.7)0.22Ventilator Dependence10.8%0.4%\<0.012.1(1.9--5.4)0.76CHF10.2%1.0%\<0.0111.2(6.4--16.7)0.02COPD12.1%3.4%\<0.013.9(2.4--6.4)0.04Hypertension77.7%48.0%\<0.013.8(2.6--5.5)0.68Acute renal failure or dialysis19.1%2.9%\<0.018.0(5.2--12.1)0.04Disseminated Cancer5.7%2.4%0.012.5(1.2--4.9)0.59Wound infection19.7%5.1%\<0.014.6(3.1--6.9)0.74Steroid3.8%2.8%0.440.79Weight loss5.7%1.8%\<0.013.3(1.7--6.7)\<0.01Bleeding Disorder17.8%5.5%\<0.013.7(2.4--5.7)0.49Preoperative RBC transfusion8.9%1.1%\<0.018.8(4.9--15.8)0.92Systemic sepsis41.4%8.9%\<0.017.2(5.2--10.0)0.06Preoperative labs Sodium \<135mEq/L17.8%5.3%\<0.013.9(2.6--5.9)0.05 BUN \>23 mg/dL52.2%16.4%\<0.015.6(4.1--7.7)0.94 Creatinine \>1.2 mg/dL47.1%14.8%\<0.015.1(3.7--7.1)0.01 Albumin \<3.5 g/dL38.7%33.1%0.14 Total Bilirubin \>1.2 mg/dL19.0%11.4%0.011.8(1.2--2.8)0.63 SGOT \>35U/L27.5%13.4%\<0.012.4(1.7--3.6)0.23 Hematocrit \<34%30.3%9.8%\<0.014.0(2.8--5.7)\<0.01 Alkaline phosphate \>126IU/L36.3%15.7%\<0.013.1(2.2--4.3)0.70 WBC \>11 × 10^9^/L50.3%18.4%\<0.014.5(3.3--6.2)0.24 Platelet \<150 × 10^9^/L15.3%6.6%\<0.012.5(1.6--4.0)0.16 INR \>1.521.5%3.5%\<0.017.6(5.0--11.5)0.13 PTT\>35 s53.1%20.2%\<0.014.4(3.2--6.2)0.12Operative time \>240 min12.1%6.3%\<0.012.0(1.3--3.3)0.02Type of Surgery0.44 General79.0%81.4% Vascular21.0%18.6%[^1]

Major predictors of CE included age \>65 years(OR 4.9, 95%CI 3.4--6.9,p \< 0.01), ASA \>3(OR 12.0, 95%CI 8.5--16.9,p \< 0.01), emergency surgery(OR 3.7, 95%CI 2.7--5.1,p = 0.01), CHF(OR 11.2, 95%CI 6.4--16.7,p = 0.02), COPD(OR 3.9, 95%CI 2.4--6.4,p = 0.04), Acute renal failure or dialysis(OR 8.0, 95%CI 5.2--12.1,p = 0.04), weight loss(OR 3.3, 95%CI 1.7--6.7,p \< 0.01), preoperative creatinine \>1.2 mg/dL(OR 5.1, 95%CI 3.7--7.1,p = 0.01), hematocrit \<34%(OR 4.0, 95%CI 2.8--5.7,p \< 0.01), and operative time \>240 min(OR 2.0, 95%CI 1.3--3.3,p = 0.02) ([Table 1](#tbl1){ref-type="table"}).

Following surgery, CE was associated with increased mortality(OR 3.5, 95%CI 1.2--6.5,p \< 0.01), pulmonary complications(OR 5.0, 95%CI 3.1--8.9,p \< 0.01), renal complications(OR 2.3, 95%CI 1.9--4.5,p \< 0.01), neurologic complications(OR 2.5, 95%CI 1.4--5.2,p \< 0.01), systemic sepsis(OR 2.2, 95%CI 1.7--4.0,p \< 0.01), postoperative RBC transfusion(OR 4.4, 95%CI 2.7--6.5,p \< 0.01), unplanned return to operating room(OR 4.0, 95%CI 2.3--6.9,p \< 0.01), and prolonged hospitalization (OR 5.5, 95%CI 3.1--8.8,p = 0.03) ([Table 2](#tbl2){ref-type="table"}). The association between CE and postoperative outcomes were similar when patients were stratified into general and vascular surgery groups ([Table 4](#tbl4){ref-type="table"}, [Table 6](#tbl6){ref-type="table"}).Table 2Postoperative outcomes contributing to CE following general and vascular surgery, univariate and multivariate analyses.Table 2Postoperative outcomesUnivariateMultivariateCE n = 157No CE n = 8284*P*OR (95% CI)*P*Mortality55.4%0.9%\<0.013.5(1.2--6.5)\<0.01Pulmonary complications59.2%2.6%\<0.015.0(3.1--8.9)\<0.01Renal complications17.2%1.2%\<0.012.3(1.9--4.5)\<0.01Neurologic complications3.2%0.1%\<0.012.5(1.4--5.2)\<0.01Thromboembolic complications2.5%0.7%\<0.013.8(1.4--8.6)0.58Systemic sepsis33.1%2.6%\<0.012.2(1.7--4.0)\<0.01Wound infection10.8%3.5%\<0.013.4(2.0--5.6)0.59Postoperative RBC transfusion32.5%4.9%\<0.014.4(2.7--6.5)\<0.01Unplanned return to operating room9.6%2.6%\<0.014.0(2.3--6.9)\<0.01Readmission5.1%4.0%0.47Length of stay \> 8days63.1%16.7%\<0.015.5(3.1--8.8)0.03[^2]

There was no significant difference between the incidence of CE among general and vascular surgery patients (p = 0.44). However, predictors of CE differed in patients who underwent general surgery compared to vascular surgery ([Table 3](#tbl3){ref-type="table"}, [Table 5](#tbl5){ref-type="table"}). Notably, ASA \>3, dependent functional status, ventilator dependence, acute renal failure or dialysis, weight loss, creatinine \>1.2 g/dL, hematocrit \<34%, INR \>1.5, and PTT \>35 s were all independent predictors of CE in patients undergoing general surgery. Significant predictors of CE after vascular surgery included age \>65 years, emergency surgery, diabetes, ventilator dependence, CHF, systemic sepsis, hematocrit \<34%, and operative time \>240 min.Table 3Patient characteristics contributing to CE following general surgery, univariate and multivariate analyses.Table 3Patient characteristicsUnivariateMultivariateCE n = 124No CE n = 6743POR (95% CI)PAge \>65years67.3%29.5%\<0.014.9(3.2--7.6)0.38BMI\>30 kg/m^2^24.2%28.8%0.34Female gender48.0%52.7%0.35Race0.48 White67.3%64.2% Black23.5%16.8% Asian8.2%13.9% Other1.0%5.0%ASA\>363.3%6.8%\<0.012.5(1.4--3.8)\<0.01Emergency surgery58.2%23.2%\<0.014.6(3.1--6.9)0.87Diabetes24.5%13.8%\<0.012.0(1.3--2.4)0.69Smoke14.3%14.5%0.95Dyspnea7.1%1.9%\<0.014.1(1.8--8.9)0.40Dependent functional status44.9%6.6%\<0.015.6(2.7--10.4)\<0.01Ventilator Dependence15.3%0.5%\<0.013.1(1.9--7.9)\<0.01CHF3.1%0.4%\<0.017.9(2.3--11.4)0.06COPD9.2%2.2%\<0.014.4(2.2--8.9)0.33Hypertension69.4%39.9%\<0.013.4(2.2--5.3)0.68Acute renal failure or dialysis15.3%1.1%\<0.012.9(1.8--3.8)\<0.01Disseminated Cancer9.2%2.8%\<0.013.5(1.7--7.0)0.45Wound infection12.2%1.4%\<0.014.6(1.1--9.1)0.35Steroid4.1%2.8%0.44Weight loss9.2%1.9%\<0.015.1(2.5--8.4)0.01Bleeding Disorder13.3%2.2%\<0.016.8(3.7--12.4)0.27Preoperative RBC transfusion9.2%0.8%\<0.0111.9(5.7--14.8)0.10Systemic sepsis52.0%9.2%\<0.0110.7(7.1--16.1)\<0.01Preoperative labs Sodium \< 135mEq/L16.3%4.4%\<0.014.3(2.5--7.4)0.99 BUN \> 23 mg/dL45.9%11.0%\<0.016.9(4.6--9.3)0.17 Creatinine \>1.2 mg/dL40.8%9.6%\<0.016.5(4.3--9.8)0.16 Albumin \<3.5 g/dL39.1%36.9%0.62 Total Bilirubin \>1.2 mg/dL22.8%12.2%\<0.012.1(1.3--3.5)0.32 SGOT \> 35U/L28.3%13.1%\<0.012.6(1.7--4.2)0.68 Hematocrit \<34%27.2%7.9%\<0.014.4(2.7--7.0)0.04 Alkaline phosphate \>126IU/L41.8%15.9%\<0.013.8(2.5--5.7)0.49 WBC \> 11 × 10^9^/L48.0%13.3%\<0.016.0(4.0--9.0)0.42 Platelet \< 150 × 10^9^/L17.3%6.1%\<0.013.2(1.9--5.5)0.18 INR \> 1.523.4%2.4%\<0.012.3(1.4--5.4)\<0.01 PTT\> 35 s45.7%14.0%\<0.015.2(3.4--7.8)0.03Operative time \> 240 min10.2%6.9%\<0.011.5(0.8--3.0)0.29[^3]Table 4Postoperative outcomes contributing to CE following general surgery, univariate and multivariate analyses.Table 4Postoperative outcomesUnivariateMultivariateCE n = 124No CE n = 6743*P*OR (95% CI)*P*Mortality60.2%0.9%5.1(1.6--7.7)\<0.01Pulmonary complications59.2%2.6%5.0(3.1--8.9)\<0.01Renal complications16.3%1.0%8.7(5.4--13.5)0.09Neurologic complications1.0%0%4.9(2.1--7.9)0.02Thrombotic complications2.0%0.7%0.13Systemic sepsis41.8%2.7%5.6(1.7--9.2)\<0.01Wound infection12.2%3.7%3.6(2.0--6.7)0.86Postoperative RBC transfusion29.6%3.5%3.5(1.3--8.1)0.02Unplanned return to operating room6.1%1.5%4.2(1.8--9.9)\<0.01Readmission4.1%3.6%0.80Length of stay \> 8days62.2%12.8%2.2(1.4--4.0)0.19[^4]Table 5Patient characteristics contributing to CE following vascular surgery, univariate and multivariate analyses.Table 5Patient characteristicsUnivariateMultivariateCE n = 33No CE n = 1541POR (95% CI)PAge \>65years81.4%63.4%0.012.5(1.3--4.9)\<0.01BMI\>30 kg/m^2^29.1%23.0%0.29Female gender50.8%43.7%0.28Race0.57White74.6%70.0%Black18.6%24.9%Asian6.8%4.4%Other0%0.7%ASA\>378.0%56.8%0.012.7(1.4--5.0)0.82Emergency surgery33.9%8.0%\<0.015.9(3.3--10.4)\<0.01Diabetes71.2%52.2%\<0.012.3(1.3--4.0)0.01Smoke18.6%26.1%0.20Dyspnea6.8%5.8%0.75Dependent functional status55.9%32.0%\<0.012.7(1.6--4.6)0.19Ventilator Dependence3.4%0.1%\<0.012.9(1.4--5.8)\<0.01CHF22.0%3.9%\<0.017.0(3.6--13.7)\<0.01COPD16.9%8.9%0.11Hypertension91.5%86.6%0.28Acute renal failure or dialysis25.4%11.3%0.012.7(1.5--4.9)0.05Disseminated Cancer0%0.5%0.59Wound infection32.2%22.3%0.18Steroid3.4%2.8%0.84Weight loss0%1.1%0.41Bleeding Disorder25.4%21.3%0.57Preoperative RBC transfusion8.5%2.3%\<0.013.9(1.5--10.4)0.18Systemic sepsis23.7%7.4%\<0.013.9(2.1--7.3)0.01Preoperative labsSodium \<135mEq/L20.3%9.5%0.042.6(1.3--4.7)0.38BUN \>23 mg/dL62.7%41.7%0.022.4(1.4--4.0)0.52Creatinine \>1.2 mg/dL57.6%39.3%0.032.1(1.2--3.6)0.74Albumin \<3.5 g/dL38.0%37.9%0.99Total Bilirubin \>1.2 mg/dL12.0%6.4%0.20SGOT \>35U/L26.0%15.9%0.12Hematocrit \<34%42.4%18.2%\<0.012.6(1.3--5.3)0.03Alkaline phosphate \>126IU/L36.0%22.7%0.07WBC \>11 × 10^9^/L54.2%42.5%0.18Platelet \<150 × 10^9^/L11.9%9.2%0.60INR \>1.518.2%7.9%0.033.1(2.8--5.4)0.06PTT\>35 s66.0%54.6%0.012.2(1.4--4.3)0.08Operative time \>240 min15.3%3.5%\<0.014.9(2.3--10.6)\<0.01[^5]Table 6Postoperative outcomes contributing to CE following vascular surgery, univariate and multivariate analyses.Table 6Postoperative outcomesUnivariateMultivariateCE n = 33No CE n = 1541*P*OR (95% CI)*P*Mortality47.5%1.1%\<0.017.3(4.0--9.2)\<0.01Pulmonary complications45.8%3.2%\<0.013.2(1.9--5.0)\<0.01Renal complications18.6%1.9%\<0.012.8(1.5--5.2)0.23Neurologic complications6.8%0.6%\<0.013.4(1.4--5.2)0.39Thrombotic complications3.4%0.5%0.023.1(1.4--5.9)\<0.01Systemic sepsis18.6%2.3%\<0.012.9(1.7--4.9)0.94Wound infection8.5%2.5%0.033.6(1.3--9.4)\<0.01Postoperative RBC transfusion37.3%11.3%\<0.014.7(2.7--8.1)0.17Unplanned return to operating room15.3%7.7%0.10Readmission6.8%5.6%0.77Length of stay \> 8days64.4%35.4%\<0.013.3(1.9--5.7)0.13[^6]Table 7vascular and general surgery current procedural terminology (CPT) codes.Table 7Surgical ProcedureCPTVascular ProceduresAmputation28805, 27880, 27882, 27884, 27886, 27590, 27592, 27594Ankle disarticulation27889Bypass graft, with other vein (Abdominal aortic and peripheral)35646, 35647, 35673, 35621, 35654, 35666, 35606, 35661, 35656, 35671, 35540, 35531, 35522, 35521, 35566, 35556, 35571, 35585Fasciotomy27600, 27602, 27496, 11044, 11043, 11042Thrombectomy or Embolectomy35875, 34421, 34101, 34201, 34203, 34151Thrombendarterectomy35331, 35361, 35371, 35372, 35355, 35341, 35302, 35305Cerebrovascular37215, 37216, 35301Transluminal angioplasty of renal or visceral artery35471Phlebectomy of varicose veins37765Open upper extremity aneurysm35011, 35045Open abdominal aortic aneurysm35102, 35131Open abdominal aortic aneurysm rupture35141,Endovascular- abdominal aorta34800, 34802, 34803, 34804, 34805, 34812, 34826, 34825Endovascular- thoracic33881, 33880Endovascular- peripheral34900, 37225, 37224, 37227, 37226, 37220, 37221, 37229, 37228, 37231, 37233, 27232Open lower extremity aneurysm35226, 33877, 35883, 35881, 35761Open thoracic aorta33877Excision- abdominal graft35907Excision- extremity graft35903AV fistula37700, 37607, 37722Other37799, 27301, 27603, 49561, 49560, 64818, 35860, 49010General SurgeryPeritoneal abscess drainage, open49020, 49060Ablation, radiofrequency47380Adrenalectomy60545, 60540, 60650, 60660Parathyroidectomy60505, 60502, 60500Appendectomy44950, 44960, 44970,Incisional hernia repair49657, 49656, 49655, 49566, 49565, 49561, 49560Ventral hernia repair49654Umbilical hernia repair49653, 49652, 49587, 49585, 49582Inguinal hernia repair49651, 49650, 49525, 49521, 49520, 49507, 49505,Spigelian hernia repair49590Epigastric hernia repair49572, 49570Femoral hernia repair49555, 49553, 49550Paraesophageal hernia repair43282, 43281Diaphragmatic hernia39541Fundoplasty43280, 43279Esophagectomy43122, 43117, 43112, 43107Hepaticojejunostomy47760, 47780Roux-Y cholangiojejunostomy47785Lymphadenectomy- axillary, cervical, transabdominal, pelvic, inguinofemoral38745, 38740, 38724, 38780, 38770, 38765, 38760, 38570,Splenectomy38120, 38115, 38100Cholecystectomy47610, 47600, 47562, 47563,Choledochotomy47420Coccygectomy27080Thyroidectomy60220, 60252, 60254, 60240, 60260, 60270, 60271, 60210Esophagectomy43107Breast reconstruction19364, 19367Enterostomy closure44650, 44620, 44625, 44626, 44227Enterectomy44120, 44125, 44202Enteroenterostomy44130Enterolysis44005, 44180Enterotomy44020, 44021, 44110Omentectomy49255Extrahepatic lesion excision47711, 47712Excision of breast or chest wall lesion, cyst, tumor, fibroadenoma19125, 19271, 19120Excision or destruction of abdominal lesions48120, 44800, 49203, 49204, 49205, 43611Excisions- other25111, 55040, 49215, 45130, 51500, 15931, 25076, 27619, 27047, 27048, 27327, 24075, 24076, 48148, 45903Laparotomy49000, 44050, 43605Pancreaticojejunostomy48548Pancreatectomy48155, 48153, 48150, 48145, 48140, 48120, 48105, 48100Mastectomy19301, 19302, 19303, 19304, 19307Mastotomy19020Breast reconstruction19357, 19367Nipple exploration19110Fistula (enterovesical, gastrocolic, intestinal, rectovaginal) closure44661, 44660, 43880, 44640, 57300, 43880, 44640, 44650Gastrectomy43631, 43632, 43633, 43622, 43621, 43775, 43774, 43771, 43770, 43644, 43633, 43632, 43631, 43622, 43621, 43620Gastrojejunostomy43860, 43848, 43820Gastrorrhaphy43840Gastrotomy43501, 43500Hepatectomy47130, 47125, 47120Colectomy44160, 44140, 44145, 44146, 44143, 44144, 44150, 44212, 44211, 44208, 44207, 44206, 44205, 44204, 44160, 44157, 44155, 44151, 44150Colostomy44320, 44340, 44345, 44346, 44188Ileostomy or jejunostomy44314, 44310, 44187Debridement11004, 11005, 11006, 11044, 11043, 11042, 11043Fasciotomy27892, 27497, 27600Proctectomy45397, 45395Proctopexy with Sigmoid resection45402, 45400Duodenectomy44010Others43999, 43659, 47379, 44238, 38129, 58956, 48100, 43605, 60600, 20102, 49010, 15757, 20005, 21501, 23031, 24077, 26990, 27301, 27365, 27372, 27603, 27604, 60660, 98957, 58956, 5894057300, 55175, 55040, 51500, 50240, 49425, 49422, 49402, 49325, 49324, 49322, 49321, 49215, 48500, 47300, 46060, 46045, 46040, 44900, 44850, 43659, 43520, 37722, 37700, 37228, 37227, 37226, 37224, 34201, 34203, 35301, 33661, 35571, 27880, 27590, 35761, 35800

5. Discussion {#sec5}
=============

Even though the 1.9% incidence of CE found in this study is consistent with previous reports \[[@bib6],[@bib13],[@bib14],[@bib18]\], the observed CE-associated mortality of 55.4% was higher than expected \[[@bib2],[@bib3],[@bib8]\]. Overall, CE was associated with significant adverse postoperative outcomes. Identified predictors of postoperative CE in general and vascular surgery included advanced age, higher ASA status, emergency surgery, CHF, COPD, ARF or dialysis, weight loss, decreased preoperative creatinine, anemia, and prolonged operative time.

Most of the identified predictors of CE in this study have been thoroughly discussed in literature; however, a few predictors notably preoperative anemia is less reported. Still, the fact that preoperative anemia contributed to CE is least surprising because its predictive prognostic values on overall postoperative adverse outcomes is well published.

Anemia is a common preoperative condition with variable etiology that has been consistently shown to impact perioperative surgical management and outcomes. It has been observed that even mild decrease in hematocrit from normal range, such as a 1% decrease, results in significant morbidity and mortality \[[@bib19],[@bib20]\]. In a study by Musallam and colleagues \[[@bib20]\] that analyzed 227,425 patients undergoing noncardiac surgery, they observed higher crude postoperative mortality (4.6% vs 0.8%) and morbidity (15.7% vs 5.3%) in preoperative anemic patients who underwent major noncardiac surgery. Beattie and colleagues \[[@bib21]\] also observed a more than a two-fold increase in mortality in anemic patients undergoing noncardiac surgery, after adjusting for confounders.

A major point to note is that anemia was significantly associated with CE, irrespective of the impact of blood transfusion. It is sometimes debated that the shared interaction between anemia and RBC transfusion contributes to anemia\'s association with adverse outcomes \[[@bib22]\]. However, since blood transfusion was not a significant predictor of postoperative CE, the present study provides credence to previous studies \[[@bib21]\] that report the detrimental effects of preoperative anemia in noncardiac surgery patients, irrespective of blood transfusion.

Additionally, the present study corroborates reports studies \[[@bib7]\] that recommend separate predictive CE risk indices and risk stratification among different surgical subspecialties. Predictors for CE greatly differed between general surgery and vascular surgery patients in our patient population. Among patients undergoing major general surgery, predictors of CE included higher ASA status, dependent functional status, ventilator dependence, acute renal failure or dialysis, weight loss, anemia, decreased serum creatinine, increased INR and increased PTT, while predictors of postoperative CE in vascular surgery included advanced age, emergency surgery, diabetes, ventilator dependence, CHF, systemic sepsis, anemia and prolonged operative time.

Findings of this study should be interpreted in the context of its strengths and limitations. First, the present study is observational in nature, which limited our ability to definitively determine causation. Second, data was obtained from a single institution, raising concerns for external validity. Last, the retrospective nature of the study did not allow us to evaluate all possible patient variables and comorbidities. It is therefore possible that some unidentified predictors may contribute to postoperative CE after general or vascular surgery. These limitations notwithstanding, this present study provides a more vigorous dataset that utilized a relatively large sample size and contained several surgical procedures in patients with different comorbidities. Results from this study can therefore be used to inform surgeons on risk stratification and optimization of perioperative surgical management.

6. Conclusion {#sec6}
=============

Postoperative CE greatly increase morbidity and mortality following major general and vascular surgery. Results of this large single-center study confirm previously published predictors of CE in patients undergoing noncardiac surgery. It is the hope of the authors that results published herein provides useful information to surgeons and allows for the necessary resources to be focused on identified at-risk patients to decrease improve surgical outcomes.
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[^1]: Abbreviations: CE, cardiac events; BMI, body mass index; ASA, American Society of Anesthesiologists; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; RBC, red blood cell; BUN, blood urea nitrogen; SGOT, aspartate aminotransferase; WBC, white blood count; INR, international normalized ratio; PTT, partial thromboplastin time.

[^2]: Abbreviation: CE, cardiac events; RBC, red blood cell.

[^3]: Abbreviations: CE, cardiac events; BMI, body mass index; ASA, American Society of Anesthesiologists; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; RBC, red blood cell; BUN, blood urea nitrogen; SGOT, aspartate aminotransferase; WBC, white blood count; INR, international normalized ratio; PTT, partial thromboplastin time.

[^4]: Abbreviation: CE, cardiac events; RBC, red blood cell.

[^5]: Abbreviations: CE, cardiac events; BMI, body mass index; ASA, American Society of Anesthesiologists; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; RBC, red blood cell; BUN, blood urea nitrogen; SGOT, aspartate aminotransferase; WBC, white blood count; INR, international normalized ratio; PTT, partial thromboplastin time.

[^6]: Abbreviation: CE, cardiac events; RBC, red blood cell.
